Tweet This study looks at anti-drug antibodies against natalizumab and suggests that loss of efficacy is one of the better predictors of the response, but suggests that looking for ADA after a suspicious event is better than routine testing. They did this study because of a case of severe disease activity after 10 infusions of…
Prof Angray Kang End of an Era
Tweet I guess this blog is about celebrating research, but sadly research is a loser today and it comes with great sadness to report the passing of ProfAngry (1960-2026) who has been one of our research buddies for many years. Angray Kang was a Professor of Immunotechnology and was an ardent Fan of Derby County…
Scientists zero in on CD29 protein marker as key driver of MS in new study
In multiple sclerosis (MS), certain disease-driving immune cells carry a protein marker called CD29, which helps them move into the brain and trigger inflammation. That is the key finding of a new study by researchers in the Netherlands, who zeroed in on the protein as a driver of MS. “We identified CD29 as a characteristic…
Is ScandiLand Ready for Generic Cladribine?
Tweet The post below has very little to do with the title of my post but it looks at what happens after rituximab and they recon that cladribine is the next most cost effective drug. People getting rituximab switch after side effects such as infections related to loss of circulating antibody or because of breakthrough…
Wrinkley Risk Factor
Tweet I have a bit of a laugh at the risk factor for MS of the week,which surfaces in this or that rag each week, This week we had a new risk factor and that is food processed but here in another one and that is facial aging ….. what next anal bleaching:-)? I did…
Making sense of moments you can’t fully explain with MS
The other day, I walked into a room and stopped. Not because I needed something but because I couldn’t remember why I was there. Does this ever happen to you? Just a moment in the kitchen trying to remember what we thought we said we wanted to make for dinner. Moments like that—those little lapses…
EBV infections and Cancer/Autoimmunity
Tweet Immune response to EBV may control what the outcome is in relation to the infection, whether it is cancer or autoimmunity. I am sorry I don’t have the time or inclination to break this down further. Kamitaki N, Tang D, McCarroll SA, Loh PR. The DNA virome varies with human genes and environments. Nature….
EMA grants PRIME status to new optic neuritis therapy privosegtor
The European Medicines Agency (EMA) has granted PRIME designation to Oculis‘ experimental treatment privosegtor for optic neuritis, a condition commonly seen in people with multiple sclerosis (MS). Optic neuritis, marked by inflammation of the optic nerve that carries signals between the eyes and the brain, can lead to lasting vision problems. While also associated with…
Personalised Medicine is the Buzz Word…but where is it in MS?
Tweet Personalized medicine has been a mantra for some years but in many cases this is just a pipe-dream. Personalization means screening to do selection and this equates to cost. It also takes time. Any screening is typically borne by the manufacturer. e.g., who pays for the genomic testing for siponimod as peoples genetics determine…
Learning to be cared for
When I look back on my life of nearly 60 years, I am struck by how much of that life has been focused on the care of others around me. The people I’ve cared for are a varied group ranging from the teams that reported to me during my 30+ year career in advertising to…